Research programme: psychedelic and empathogenic compounds - Terran Biosciences
Latest Information Update: 30 Aug 2023
At a glance
- Originator Terran Biosciences
- Class Antidepressants; Ethers; Small molecules; Tryptamines
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurological disorders; Psychiatric disorders
Most Recent Events
- 29 May 2023 Terran Biosciences reports the publication of a patent application number WO 2023 092 044 covering MDMA and its derivatives
- 26 May 2023 Preclinical trials in Neurological disorders in USA (Unspecified route) (Terran Biosciences pipeline, June 2023)
- 26 May 2023 Preclinical trials in Psychiatric disorders in USA (Unspecified route) (Terran Biosciences pipeline, June 2023)